Medovex Corporation (OTCMKTS:MDVX) Sellers Covered 39.69% of Their Shorts

February 15, 2018 - By Clifton Ray

The stock of Medovex Corporation (OTCMKTS:MDVX) registered a decrease of 39.69% in short interest. MDVX’s total short interest was 177,800 shares in February as published by FINRA. Its down 39.69% from 294,800 shares, reported previously. With 106,600 shares average volume, it will take short sellers 2 days to cover their MDVX’s short positions. The short interest to Medovex Corporation’s float is 1.58%.

The stock decreased 10.42% or $0.05 during the last trading session, reaching $0.43. About 11,571 shares traded. Medovex Corporation (OTCMKTS:MDVX) has risen 3.33% since February 15, 2017 and is uptrending. It has underperformed by 13.37% the S&P500.

MedoveX Corporation, through its subsidiaries, focuses on developing medical devices primarily in the United States and Europe. The company has market cap of $9.08 million. It offers DenerveX device, a disposable single-use kit for the treatment of various medical applications, including pain relief. It currently has negative earnings. The firm serves healthcare providers, physicians, and third-party payors.

More notable recent Medovex Corporation (OTCMKTS:MDVX) news were published by: Globenewswire.com which released: “Medovex Corporation Presents Initial Data on the DenerveX® System During …” on February 13, 2018, also Quotes.Wsj.com with their article: “News Medovex Corp.MDVX” published on February 03, 2015, Marketwired.com published: “Medovex Corporation DenerveX System First Cases to Commence in Germany” on July 25, 2017. More interesting news about Medovex Corporation (OTCMKTS:MDVX) were released by: Marketwired.com and their article: “Medovex Corporation Receives CE Mark Approval for DenerveXâ„¢ System” published on June 05, 2017 as well as Globenewswire.com‘s news article titled: “Medovex Corporation Submits IDE with the Food and Drug Administration for its …” with publication date: November 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.